RT Journal Article
SR Electronic
T1 Spleen Dose–Volume Parameters as a Predictor of Treatment-related Lymphopenia During Definitive Chemoradiotherapy for Esophageal Cancer
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 1519
OP 1525
DO 10.21873/invivo.11409
VO 32
IS 6
A1 TETSUO SAITO
A1 RYO TOYA
A1 NAOYA YOSHIDA
A1 TAKASHI SHONO
A1 TOMOHIKO MATSUYAMA
A1 SATOSHI NINOMURA
A1 TAKAHIRO WATAKABE
A1 YUTAKA SASAKI
A1 HIDEO BABA
A1 NATSUO OYA
YR 2018
UL http://iv.iiarjournals.org/content/32/6/1519.abstract
AB Aim: Our study sought to identify dosimetric predictors of treatment-related lymphopenia during chemoradiotherapy for esophageal cancer. Materials and Methods: Patients with esophageal cancer who had received definitive chemoradiotherapy at our Institution were retrospectively assessed. The absolute volume of the spleen, body, and bone marrow that had received 5, 10, 20, and 30 Gy and the mean splenic dose were recorded. Results: Multivariate linear regression analysis revealed that docetaxel use and spleen dose–volume parameters (V5, V10, V20, V30, and mean splenic dose) were significant independent factors negatively influencing the absolute lymphocyte count at nadir. An increase of 1 Gy in mean splenic dose predicted a 2.9% decrease in nadir absolute lymphocyte count. Univariable logistic regression analysis showed that the mean splenic dose was a significant predictor of grade 4 lymphopenia. None of the body or bone marrow dose–volume parameters significantly predicted lymphopenia. Conclusion: Higher spleen dose–volume parameters were associated with severe lymphopenia during chemoradiotherapy.